| Phase 3 |
| NCT06521255 |
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With… |
DLBCL |
Recruiting |
| NCT06775860 |
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis |
Atopic Dermatitis |
Recruiting |
| NCT06082102 |
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined… |
Relapsed/Refractory Marginal Zone Lymphoma |
Recruiting |
| NCT06842199 |
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque… |
Plaque Psoriasis Patients |
Recruiting |
| Phase 2/3 |
| NCT07047612 |
ICP-332 in Subjects With Non-segmental Vitiligo |
Non Segmental Vitiligo |
Recruiting |
| NCT06378138 |
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic… |
Hematologic Malignancies |
Recruiting |
| NCT07378527 |
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous… |
Chronic Spontaneous Urticaria (CSU) |
Recruiting |
| Phase 2 |
| NCT05552937 |
Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients… |
DLBCL |
Recruiting |
| NCT05678270 |
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic… |
Intrahepatic Cholangiocarcinoma (ICC) |
Recruiting |
| NCT05688696 |
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus… |
Systemic Lupus Erythematosus, SLE |
Recruiting |
| NCT07251998 |
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe… |
Plaque Psoriasis |
Recruiting |
| NCT07440537 |
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus… |
Cutaneous Lupus Erythematosus (CLE) |
Recruiting |
| NCT07082686 |
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or… |
Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
Recruiting |
| NCT07236099 |
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis |
Prurigo Nodularis (PN) |
Recruiting |
| NCT07727486 |
A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary… |
Primary Sjögren's Syndrome |
Not Yet Recruiting |
| Phase 1/2 |
| NCT04685226 |
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors |
Solid Tumors |
Recruiting |
| NCT05745623 |
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System… |
Advanced Solid Tumors Harboring NTRK Fusion |
Recruiting |
| NCT07617493 |
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors |
Advanced Solid Tumor |
Recruiting |
| NCT05210868 |
A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's… |
Hematoma |
Active, Not Recruiting |
| NCT06845241 |
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or… |
Relapsed or Refractory Non-Hodgkin Lymphoma |
Not Yet Recruiting |
| NCT04014205 |
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell… |
Part 1：r/r B-cell Malignancies |
Active, Not Recruiting |
| Phase 1 |
| NCT05690581 |
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced… |
Advanced Solid Tumors and Hematologic Malignancies |
Recruiting |
| NCT05728658 |
The Study of ICP-248 in Patients With Mature B-cell Malignancies |
Hematological Malignancies |
Recruiting |
| NCT06656494 |
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid… |
Acute Myelogenous Leukemia |
Recruiting |
| NCT07535099 |
Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in… |
Health Services Research |
Recruiting |